The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited a […]

Join us at the inaugural Portfolio Strategy & Decision Making for Biopharma Summit - the must-attend event for pharma and biotech leaders seeking to sharpen their portfolio strategies in today’s […]

Liquid biopsies are revolutionizing clinical trials, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification, ensuring they receive […]